medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2014-7-39-42medsovet-598Research ArticleНЕВРОЛОГИЯNEUROLOGYАлгоритм антитромботической терапии у пациентов с ишемическим инсультом после системного тромболизисаAlgorithm for antithrombotic therapy in patients with ischemic stroke after thrombolysisДомашенкоМ. А.DomashenkoMAnoemail@neicon.ruМаксимоваМ. Ю.MaksimovaMYnoemail@neicon.ruТанашянМ. М.TanashyanMMnoemail@neicon.ruНаучный центр неврологии Российской академии медицинских наукРоссияNeurology Research Center, Russian Academy of Medical SciencesRussian Federation201430122014073942Copyright © Домашенко М.А., Максимова М.Ю., Танашян М.М., 20142014Домашенко М.А., Максимова М.Ю., Танашян М.М.Domashenko M., Maksimova M., Tanashyan M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/598

Работа поддержана Грантом Президента Российской Федерации по государственной поддержке ведущих научных школ РФ НШ-6088.2014.7 Системная тромболитическая терапия пациентов с ишемическим инсультом является эффективным методом лечения у определенной категории больных в течение первых 4,5 ч после появления первых симптомов заболевания. Вместе с тем, согласно протоколу ее проведения, назначение любых антитромботических препаратов в течение первых суток после тромболизиса противопоказано. С другой стороны, по истечении 24 ч после проведения тромболизиса остается необходимость назначения антитромботических препаратов с целью вторичной профилактики инсульта. Нами продемонстрирован собственный опыт применения тромбоцитарных антиагрегантов у больных с ишемическим инсультом после тромболитической терапии.

Systemic thrombolytic therapy in patients with ischemic stroke is an effective treatment for a certain category of patients during the first 4.5 hours after the symptom onset. However, according to the treatment protocol, administration of any antithrombotic drugs during the first days after thrombolysis is contraindicated. At the same time, 24 hours after thrombolysis the need remains for the intake of antithrombotic agents for the purpose of secondary prophylaxis of stroke. We described our own experience in the use of antiplatalets in patients with ischemic stroke after thrombolytic therapy.

ишемический инсультсистемный тром-болизисантиагрегантыацетилсалициловая кислотаischemic strokesystemic thrombolysisantiplatelet agentsacetylsalicylic acidReferencesGuidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008-2009. URL: http://www.eso-stroke. org/recommendations.Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008-2009. URL: http://www.eso-stroke. org/recommendations.Jauch E et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2013, 44: published online January 31, 2013.Jauch E et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke, 2013, 44: published online January 31, 2013.Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology, 2010, 9: 866-74.Ahmed N et al. Implementation and outcome of thrombolysis with alteplase 3-4,5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurology, 2010, 9: 866-74.Суслина З.А., Высоцкая В.Г Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии. Клиническая медицина, 1983, 9: 51-59.Суслина З.А., Высоцкая В.Г Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии. Клиническая медицина, 1983, 9: 51-59.International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet, 1997, 349: 1569-1581.International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet, 1997, 349: 1569-1581.CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet, 1997, 349: 1641-1649.CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet, 1997, 349: 1641-1649.Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинической и экспериментальной неврологии, 2007, 1: 17-22.Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему. Анналы клинической и экспериментальной неврологии, 2007, 1: 17-22.Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 2002, 59: 862-67.Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology, 2002, 59: 862-67.Rothwell P.M. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet, 2007, 370: 1432-42.Rothwell P.M. et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet, 2007, 370: 1432-42.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333: 1581-7.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med, 1995, 333: 1581-7.Lees K et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375: 1695-703.Lees K et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, 2010, 375: 1695-703.Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 1962, 194: 927-9.Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 1962, 194: 927-9.O'Brien J. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J Clin Pathol., 1964, 17: 275-81.O'Brien J. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J Clin Pathol., 1964, 17: 275-81.

The authors declare that there are no conflicts of interest present.